Midkine as a driver of age-related changes and increase in mammary tumorigenesis
- PMID: 39366375
- PMCID: PMC11560576
- DOI: 10.1016/j.ccell.2024.09.002
Midkine as a driver of age-related changes and increase in mammary tumorigenesis
Abstract
Aging is a pivotal risk factor for cancer, yet the underlying mechanisms remain poorly defined. Here, we explore age-related changes in the rat mammary gland by single-cell multiomics. Our findings include increased epithelial proliferation, loss of luminal identity, and decreased naive B and T cells with age. We discover a luminal progenitor population unique to old rats with profiles reflecting precancerous changes and identify midkine (Mdk) as a gene upregulated with age and a regulator of age-related luminal progenitors. Midkine treatment of young rats mimics age-related changes via activating PI3K-AKT-SREBF1 pathway and promotes nitroso-N-methylurea-induced mammary tumorigenesis. Midkine levels increase with age in human blood and mammary epithelium, and higher MDK in normal breast tissue is associated with higher breast cancer risk in younger women. Our findings reveal a link between aging and susceptibility to tumor initiation and identify midkine as a mediator of age-dependent increase in breast tumorigenesis.
Keywords: aging; breast cancer risk; breast tumorigenesis; mammary tumors; midkine; single-cell profiling.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests K.P. serves on the Scientific Advisory Board of Ideaya Biosciences and Scorpion Therapeutics, holds equity options in Scorpion Therapeutics and Ideaya Biosciences, and receives sponsored research funding from Novartis where she also consults. L.E.S. is current employee of Astra-Zeneca. H.W.L. receives research funding from Novartis.
Similar articles
-
Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.Breast Cancer Res. 2018 May 16;20(1):41. doi: 10.1186/s13058-018-0966-2. Breast Cancer Res. 2018. PMID: 29769144 Free PMC article.
-
Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.Cancer Med. 2025 Jul;14(13):e71034. doi: 10.1002/cam4.71034. Cancer Med. 2025. PMID: 40620228 Free PMC article.
-
Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models.Breast Cancer Res. 2025 Jan 3;27(1):1. doi: 10.1186/s13058-024-01933-3. Breast Cancer Res. 2025. PMID: 39754221 Free PMC article.
-
Significance of Midkine Signaling in Women's Cancers: Novel Biomarker and Therapeutic Target.Int J Mol Sci. 2025 May 17;26(10):4809. doi: 10.3390/ijms26104809. Int J Mol Sci. 2025. PMID: 40429950 Free PMC article. Review.
-
Alcohol consumption and cancer risk: understanding possible causal mechanisms for breast and colorectal cancers.Evid Rep Technol Assess (Full Rep). 2010 Nov;(197):1-151. Evid Rep Technol Assess (Full Rep). 2010. PMID: 23126574 Free PMC article.
Cited by
-
Immuno-oncology recapitulates ontogeny: Modern cell and gene therapy for cancer.Mol Ther. 2025 May 7;33(5):2229-2237. doi: 10.1016/j.ymthe.2025.03.042. Epub 2025 Mar 27. Mol Ther. 2025. PMID: 40156188 Review.
-
Ageing, immune fitness and cancer.Nat Rev Cancer. 2025 Aug 14. doi: 10.1038/s41568-025-00858-z. Online ahead of print. Nat Rev Cancer. 2025. PMID: 40813902 Review.
-
Integrating Bulk RNA and Single-cell transcriptome to explore the role of glycan-related genes in lung adenocarcinoma.J Cancer. 2025 Jul 24;16(11):3314-3328. doi: 10.7150/jca.115989. eCollection 2025. J Cancer. 2025. PMID: 40861802 Free PMC article.
-
CITEgeist: Cellular Indexing of Transcriptomes and Epitopes for Guided Exploration of Intrinsic Spatial Trends.bioRxiv [Preprint]. 2025 Feb 17:2025.02.15.638331. doi: 10.1101/2025.02.15.638331. bioRxiv. 2025. PMID: 40027773 Free PMC article. Preprint.
-
The discovery and characterization of HBS-101, a novel inhibitor of midkine, as a therapeutic agent for the treatment of triple negative breast cancer.Mol Cancer Ther. 2025 Apr 30:10.1158/1535-7163.MCT-25-0130. doi: 10.1158/1535-7163.MCT-25-0130. Online ahead of print. Mol Cancer Ther. 2025. PMID: 40304496
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases